Protein ADM2

Also known as: Intermedin, ADM2, Q7Z4H4

**Mechanism of Action** Protein ADM2 (Intermedin) is a peptide hormone that exerts its biological effects primarily through activation of the calcitonin receptor-like receptor (CALCRL) in complex with receptor activity-modifying proteins (RAMPs). This receptor system mediates downstream signaling pathways involved in vasodilation, fluid homeostasis, and gastrointestinal motility. The peptide is structurally related to adrenomedullin and calcitonin gene-related peptide, sharing overlapping receptor interactions but with distinct tissue-specific actions. **Key Research Findings** Preclinical studies indicate that ADM2 modulates cardiovascular function by inducing hypotension and increasing cardiac output, likely via nitric oxide-dependent vasorelaxation. In gastrointestinal models, it regulates gastric emptying and intestinal fluid secretion. Despite its experimental status, no PubMed-indexed human or animal studies are currently available, suggesting limited published data. Research remains confined to early-stage characterization of its receptor pharmacology and physiological roles. **Clinical Relevance** ADM2 has potential therapeutic applications in conditions involving vascular dysregulation, such as hypertension or heart failure, and gastrointestinal disorders like motility dysfunction. However, its experimental designation and absence of peer-reviewed clinical evidence preclude any current medical use. Further studies are required to validate its safety, efficacy, and translational value. For research purposes only — not medical advice.

Key data

Mechanism of action

Intermedin/ADM2 is a peptide hormone that plays a role as physiological regulator of gastrointestinal and cardiovascular bioactivities mediated by the CALCRL-RAMPs receptor complexes (PubMed:14615490). Activates the cAMP-dependent pathway through interaction with CALCRL-RAMP3 receptor complex (PubMed:14615490)

Frequently asked questions

Related peptides